Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J, Moreno I, Fernandez-Aceñero MJ, Rodriguez-Remirez M, Borrero-Palacios A, Cebrian A, Gomez Del Pulgar T, Del Puerto-Nevado L, Li W, Puime-Otin A, Perez N, Soengas MS, Garcia-Foncillas J. Martinez-Useros J, et al. BMC Cancer. 2018 Feb 6;18(1):144. doi: 10.1186/s12885-018-4048-8. BMC Cancer. 2018. PMID: 29409457 Free PMC article.
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J. del Puerto-Nevado L, et al. Br J Cancer. 2014 May 27;110(11):2700-7. doi: 10.1038/bjc.2014.225. Epub 2014 May 1. Br J Cancer. 2014. PMID: 24786599 Free PMC article.
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J. Martinez-Useros J, et al. BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965. BMC Cancer. 2014. PMID: 25515240 Free PMC article.
Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.
Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. Aguilera Ó, et al. Oncotarget. 2015 Mar 20;6(8):5903-17. doi: 10.18632/oncotarget.3464. Oncotarget. 2015. PMID: 25788273 Free PMC article.
Morphological aspects of the hepatic response to neoadjuvant therapy.
Fernández-Aceñero MJ, Cortés-Guiral D, Muñoz LE, Martínez-Useros J, Pastor-Idoate C. Fernández-Aceñero MJ, et al. Pathol Res Pract. 2015 Sep;211(9):665-70. doi: 10.1016/j.prp.2015.06.007. Epub 2015 Jun 16. Pathol Res Pract. 2015. PMID: 26163186
Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant".
Martinez-Useros J, Georgiev-Hristov T, Borrero-Palacios A, Fernandez-Aceñero MJ, Rodríguez-Remírez M, Del Puerto-Nevado L, Cebrian A, Gomez Del Pulgar MT, Cazorla A, Vega-Bravo R, Perez N, Celdran A, Garcia-Foncillas J. Martinez-Useros J, et al. Medicine (Baltimore). 2015 Nov;94(45):e1972. doi: 10.1097/MD.0000000000001972. Medicine (Baltimore). 2015. PMID: 26559273 Free PMC article.
55 results